One year ago, the Brazilian House of Representatives finally approved the Biosafety Bill, which made it legal in Brazil to work with human embryonic stem cells (hESCs) and to derive hESC lines from surplus or nonviable human embryos stored for three or more years in IVF (in vitro fertilization) clinics. Under the new law, no human embryo can be created for research purposes, and therapeutic cloning using somatic cell nuclear transfer is still forbidden. When the last vote on the Biosafety Bill was cast, the audience erupted into cheers as the result was announced: 352 in favor of passing the law, 60 against. Patients with muscular dystrophy joined hands with geneticist Mayana Zatz, a leading muscular dystrophy researcher, and with the Science and Technology Minister at that time, Eduardo Campos, to celebrate a landmark victory for Brazil's scientific research community. After years of campaigning, scientists and patient advocates had obtained the right to produce and work with hESC lines in Brazil. However, one year after this encouraging victory, the applause has evaporated because not a single hESC colony has been derived so far. What are the reasons for this delay?
Within one month of the vote, the National Council for Scientific and Technological Development (better known by the old acronym CNPq), Brazil's equivalent to the U.S. National Science Foundation, earmarked $5 million for stem cell research and published a call for cell therapy projects. Half of the funds were to come from the Science and Technology Ministry and half from the Health Ministry, which was eager to reap public health benefits from the new field of research, particularly as patient lobby groups had helped to get the Biosafety Bill passed.
The selection committee for the CNPq stem cell grants received 106 proposals from research groups all over Brazil. However, only 41 projects made it through to the next stage. The selection committee was composed of six biology researchers working at well-regarded institutions such as the University of São Paulo (USP) and the Federal University of Rio de Janeiro (UFRJ). The committee included Dr. Anibal Gil Lopes, which raised concerns in scientific circles because although Dr. Lopes is a respected researcher at UFRJ, he is also a Catholic priest and a member of the Vatican's Pontifical Academy Pro Vita. When the committee announced which projects would be funded at the end of August last year, CNPq found itself under heavy fire. Of the 41 projects funded, only three explicitly involved the study of ESCs and one of these was a proposal to grow rabbit (not human) ESCs on a substrate of iron nanoparticles to establish whether ESC colonies can be grown in the absence of mouse feeder cells. Surprisingly, the proposal by Mayana Zatz of USP to derive hESC lines from human embryos was turned down, as was the proposal by Lygia da Veiga Pereira, an experienced stem cell researcher also from USP and Zatz's former collaborator. The feedback Pereira received from the selection committee filled a single line: "The proposal is plagued by lack of originality and does not show evidence of how the availability of those [hES] cells will be able to impact breakthroughs in human health." Says Pereira, "The result of the call for projects had disappointed many of us."
José Eduardo Krieger at INCORa renowned cardiology clinical research center linked to USP-also was dissatisfied with the selection committee's initial decision not to fund his proposal to study the biology of hESCs. He was particularly surprised about the absence of projects directed at the derivation of hESCs among the list of funded projects. "Such an important thing could never have been left out, since this is a key reagent in this area if we want to succeed in the development of new therapeutic approaches for adult organ repair." Krieger received a similar response to his grant proposal stating that although his project had merit the team had not enough expertise and experience to carry it out. Krieger, the head of the Genetics and Molecular Cardiology Lab at INCOR, was surprised by the allegation, given that his group had been chosen a few months earlier to run one of the four arms of a 1,200-patient, $6 million clinical trial to treat cardiomyopathy with adult human bone marrow stem cells, sponsored by the very same ministries.
Zatz, Pereira, and Krieger, together with nine other principal investigators, appealed their decisions. The CNPq selection committee made public their final decision at the end of November last year: Four appeals were accepted, including those of the three USP research groups. Subsequently, CNPq argued that the reversal was due solely to the new scientific arguments provided by the research groups that appealed, and
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not to the controversy triggered by the first decision in August.
Given the difficulties surrounding the launch of hESC research in Brazil, Pereira and her collaborator Stevens Rehen are spearheading an initiative to reach out to the private sector in the form of a Stem Cell Virtual Institute (IVCT, http://www.ivct.com.br). The idea behind this network of stem cell investigators is to attract private funds to finance the advancement of hESC research in Brazil, primarily through scientific collaborations and meetings, as well as through development and dissemination of protocols to promote standardization and to assure comparability of research outputs among laboratories throughout the country. "IVCT will also provide an interface to discuss ethical issues and cellular therapies with physicians, the public, biotech companies and the press in Brazil," says Rehen. Thirty-five Brazilian laboratories have expressed interest in joining IVCT, whose Board is now in the process of uploading protocols and references onto the new website as well as information about plans to convene a meeting to discuss the first research results in a few months.
Meanwhile, hESC research in Brazil is facing another major hurdle. Claudio Fonteles, in one of his last acts as Brazil's Attorney General, brought a so-called "ação direta de inconstitucionalidade" (direct unconstitutionality claim) against the Biosafety Law before the Federal Supreme Court in May last year. A devout Catholic, his petition argued that the permission to destroy human blastocysts to derive hESCs offended the basic constitutional tenet of life's inviolability: "The central thesis in the present claim is that human life happens in and starting with [ Thus, hESC research in Brazil is standing on rather uncertain terrain. Colonies of hESCs received from laboratories outside of Brazil have just started to be unfrozen. Only in January this year, did CNPq begin to channel research money to the 45 research groups whose projects had been approved. But even if the research money is flowing, the two USP projects that aim to derive hESC lines remain in jeopardy under the pending Supreme Court decision.
Although hESC research faces numerous roadblocks, research on adult stem cells continues to thrive in Brazil. Several clinical studies have yielded at least some successes using transplants of adult bone marrow stem cells to treat a host of diseases from diabetes and cardiomyopathy to hepatic cirrhosis. One of the biggest clinical projects currently underway, funded by the Ministry of Health and the Ministry of Science and Technology, is to use adult bone marrow stem cells to treat cardiomyopathies. More than 30 groups across the country are now part of the 1,200-patient Randomized Multicenter Study on Cellular Therapy in Cardiomyopathies (EMRTCC). There are four arms to the clinical trialpatients with dilated cardiomyopathy due to Chagas disease (a serious illness caused by a trypanosome parasite that is endemic in much of South America), and patients with general dilated cardiomyopathy, chronic ischemia, or acute myocardial infarction. There are 300 patients per arm: 150 will receive injections of autologous bone marrow stem cells into the heart, and 150 will serve as the control group. The EMRTCC clinical trial follows preliminary safety studies with small numbers of patients, which showed that the procedure is safe.
In Brazil, clinical studies using adult stem cells are not overseen by ANVISA, the agency equivalent to the FDA in the United States, because the injection of adult bone marrow stem cells into the heart is considered an extension of existing therapies. The sole requirement for this type of clinical study is approval from the National Council for Ethics in Research (CONEP).
About 100 patients have undergone the adult bone marrow stem cell injections so far, less than 10 percent of the total 1,200. In spite of that, the Health Ministry boasts that Brazil is doing pioneer research and taking a leading role in the development of stem cell therapies. Highly publicized estimates point to the goal of saving 200,000 lives over three years, once the technology is available, and saving $200 million annually in heart transplant costs. The work with adult stem cells has certainly proved an efficient way to gather public support for stem cell research in general. For instance, Brazil's most popular weekly news magazine Veja portrayed stem cells on the cover of its November 23, 2005 issue with the headline "The medicine that operates miracles."
One pressing issue that needs to be addressed is the confusion among the general public regarding the difference between hESCs and adult stem cells, and how long it will be before either stem cell population is in routine clinical use. Krieger at INCOR considers that the nuanced differences between embryonic and adult stem cells have never been thoroughly laid out to the public. "It was a collective failure. I often talk to journalists, but have not been sufficiently convincing, as those nuances have never made it to print." Several participants discussed this issue at the 1st Brazilian Meeting on Human Embryonic Stem Cells, in Rio de Janeiro in November of last year. Striking a cautionary note was Luiz Eugênio Mello, a neuroscientist with the Federal University of São Paulo (UNIFESP) and vice president of the Brazilian Federation of Experimental Biology Societies (FeSBE). He hoped for expectations to be less "excessive" so as not to turn stem cell research into "another gene therapy,"
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Zatz, however, counters "All the patients who were there [in Congress] knew perfectly well that we were defending the research. One has to consider that we deal with a population that has almost no degree of education, and maybe they think that we are going to inject hESCs and cure them immediately," she says. "On the other hand, if we had not been very emphatic, perhaps we would not have won as we did." Not all Brazilian scientists are jumping on the stem cell bandwagon, however. Luiz Fernando Lima Reis, from the Ludwig Institute for Cancer Research and chair of the controversial CNPq selection committee, would rather see more emphasis on basic research. "My personal belief is that Brazil, as any other country in the world, needs to investigate the biology of stem cells. I think there is hype and precipitation in the clinical use, or alleged clinical use, of stem cells. We don't know yet the biology of these cells," he said in an interview. "There is an anxiety to treat people. We are cutting corners that are of major importance."
With a final decision by the Federal Supreme Court expected shortly and funds beginning to flow from CNPq, Brazilian stem cell research should be able to take off at last. It remains to be seen whether initiatives such as IVCT will succeed in engaging the general public in the debate, such that societal support for this type of research can be based on solid information and not on unwarranted expectations about the powers of biomedicine.
